The SerOzNET study seeks to better understand the safety and efficacy of the COVID-19 vaccines in people with cancer.
- Conditions
- CancerOncologyCOVID-19Cancer - Any cancerCancer - Leukaemia - Chronic leukaemiaCancer - MyelomaCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaCancer - Children's - Leukaemia & Lymphoma
- Registration Number
- ACTRN12621001004853
- Lead Sponsor
- Monash Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 510
Aged 5 years or over as per ATAGI guidelines for COVID-19 vaccination (January 10, 2022)
• Able to give informed consent (parent/guardian for participants < 16 years)
• Eligible for government COVID-19 vaccination program and willing to receive the
vaccine
• Cancer diagnosis fitting one of the study cohorts (solid tumour, haematological
malignancy, currently receiving chemotherapy, currently receiving immunotherapy &
known allergic reaction to PEG or Polysorbate)
•Not appropriate for serial peripheral blood collections, due to clinical reasons such as
severe anaemia, poor venous access or other, as determined by the patient’s
oncologist or haematologist.
•Life expectancy estimated to be greater than 12 months
•Individual is not able to provide informed consent
•Pregnancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method